logo_h.jpg
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
21 déc. 2023 08h00 HE | Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive...
Healis Therapeutics selected to speak on opening day of 2024 Biotech Showcase in San Francisco
05 déc. 2023 08h00 HE | Healis Therapeutics
Healis Co-Founders Sebastian De Beurs and Dr. Eric Finzi will be presenting on the company's neurotherapeutics pipeline and clinical development.
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10 janv. 2022 06h30 HE | Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
05 janv. 2022 09h00 HE | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
Logo.jpg
INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022 
05 janv. 2022 09h00 HE | Invectys, Inc.
Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
VIR_logo_large.jpg
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h02 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P....
logo_new.jpg
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
15 janv. 2020 01h00 HE | ObsEva SA
  Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...
logo_new.jpg
ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020
07 janv. 2020 01h00 HE | ObsEva SA
Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
AskBio-Logo-with-NoTagline_Black_Large.png
AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
02 janv. 2020 16h53 HE | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...